Clario Executive and Leadership Team

Michael Woehler, the Chief Executive Officer at Clario, directs the overarching corporate strategy to advance endpoint technology solutions for clinical trials. Woehler architects the long-term vision for integrating scientific expertise with global scale, ensuring pharmaceutical and biotechnology partners receive robust data for regulatory approvals. By overseeing the executive leadership team, the Chief Executive Officer maintains alignment across all departments to support the company mission of transforming lives through clinical evidence. Woehler drives the expansion of the Trial Anywhere approach, facilitating decentralized and hybrid trial models across North America, Europe, and the Asia Pacific region. This leadership role involves constant evaluation of market trends to maintain a competitive edge in the clinical technology sector. Through rigorous focus on operational excellence and innovation, Michael Woehler secures the company position as a leader in delivering high-quality clinical evidence for complex medical research programs.

Nate Goldenman, the President & Chief Executive Officer at Clario, manages the execution of strategic initiatives focused on scaling endpoint technology platforms. Goldenman oversees the integration of technology and operational workflows to support diverse clinical trial requirements, ranging from site-based to decentralized models. The President & Chief Executive Officer drives organizational efficiency by aligning internal resources with the needs of global biotechnology and medical device partners. Nate Goldenman ensures that the company maintains a strong presence in international markets, including North America and the Asia Pacific region, by optimizing service delivery models. This role involves close collaboration with the board to refine business objectives and enhance the value proposition for clients. By prioritizing technological advancement and scientific rigor, Goldenman strengthens the ability of the organization to generate reliable clinical evidence, ultimately supporting the successful delivery of life-changing medical therapies to patients worldwide.

Christopher Fikry, the President & Chief Executive Officer at Clario, leads the strategic development of clinical trial solutions that leverage advanced endpoint technology. Fikry architects initiatives that bridge the gap between complex scientific requirements and practical technology implementation for global pharmaceutical partners. The President & Chief Executive Officer oversees the deployment of the Trial Anywhere framework, ensuring seamless data collection across hybrid and decentralized trial environments. Christopher Fikry drives the company mission by fostering a culture of innovation that addresses the evolving needs of the medical device and biotechnology industries. This leadership position requires constant engagement with global operations to ensure consistent quality standards across North America, Europe, and the Asia Pacific region. By focusing on the intersection of technology and clinical research, Fikry ensures the organization remains at the forefront of the industry, providing the essential evidence required for critical regulatory approvals and patient safety.

Joshua Collins, the Chief Executive Officer & Founder at Clario, establishes the foundational principles and strategic direction for the company endpoint technology platform. Collins drives the development of innovative solutions that enable pharmaceutical and biotechnology partners to conduct clinical trials with greater precision and efficiency. The Chief Executive Officer & Founder oversees the long-term growth trajectory, ensuring the organization maintains its commitment to scientific expertise and global scale. Joshua Collins architects the company approach to decentralized and hybrid trial models, facilitating the generation of rich clinical evidence across diverse geographic markets including North America and Europe. This role involves shaping the corporate culture and maintaining strong relationships with key industry stakeholders to support ongoing innovation. By focusing on the core mission of transforming lives through technology, Collins ensures the company continues to deliver high-quality clinical evidence that meets the rigorous demands of modern regulatory environments.

Alexander Brito, the Chief Financial Officer, Rei Bookkeeping & Fractional Services at Clario, manages the financial health and fiscal strategy of the organization. Brito architects financial models that support the investment in endpoint technology and the expansion of global clinical trial services. The Chief Financial Officer, Rei Bookkeeping & Fractional Services oversees budgeting, financial reporting, and capital allocation to ensure the company maintains the resources necessary for sustained growth. Alexander Brito drives financial transparency and accountability, providing the data-driven insights required for strategic decision-making by the executive team. This role involves monitoring the economic performance of operations across North America, Europe, and the Asia Pacific region to ensure alignment with corporate objectives. By maintaining a disciplined approach to financial management, Brito supports the company mission of delivering high-quality clinical evidence, ensuring the organization remains financially stable while continuing to innovate within the competitive clinical research technology market.

Nayan Nanavati, the Chief Operating Officer at Clario, directs the internal operational infrastructure required to support complex clinical trial technology solutions. Nanavati architects scalable processes that enhance the delivery of endpoint technology services to pharmaceutical and medical device partners. The Chief Operating Officer oversees the integration of technology and operational teams to ensure high-quality evidence generation across decentralized and site-based trial models. By managing the day-to-day execution of business functions, Nanavati drives efficiency and consistency across global operations in North America, Europe, and the Asia Pacific region. This leadership role involves optimizing resource allocation and streamlining workflows to meet the demanding timelines of clinical research. Nayan Nanavati ensures that the operational framework remains robust and adaptable, allowing the company to maintain its competitive advantage while supporting the overarching mission of delivering reliable clinical evidence for critical regulatory approvals.

Angelo Stortini, the Chief Operating Officer & Senior VP at Clario, leads the strategic implementation of supply chain and logistics frameworks for clinical trial technology. Stortini architects the operational systems that facilitate the deployment of endpoint technology across diverse trial sites, ensuring seamless data collection and management. The Chief Operating Officer & Senior VP oversees the coordination between technology teams and clinical partners to maintain high standards of service delivery. Angelo Stortini drives the optimization of global logistics, ensuring that the company maintains a reliable presence across North America, Europe, and the Asia Pacific region. This leadership role involves managing complex operational challenges to support the company mission of generating rich clinical evidence. By focusing on the practical application of technology in clinical settings, Stortini ensures that the organization meets the specific needs of biotechnology and medical device partners, ultimately contributing to the success of critical clinical research programs.

Matthew Borer, the Senior Commercial Director - Strategic Chief Revenue Officer Partnerships at Clario, directs the commercial strategy and revenue growth initiatives through high-level industry partnerships. Borer architects collaborative frameworks that connect the company endpoint technology platform with key pharmaceutical and biotechnology stakeholders. The Senior Commercial Director - Strategic Chief Revenue Officer Partnerships oversees the development of strategic alliances that expand the market reach of the organization across North America, Europe, and the Asia Pacific region. Matthew Borer drives revenue generation by aligning commercial efforts with the specific needs of clients conducting decentralized and hybrid clinical trials. This role involves managing complex negotiations and maintaining long-term relationships with partners to ensure sustained business growth. By focusing on the commercial impact of clinical technology, Borer supports the company mission of delivering high-quality evidence, ensuring that the organization remains a preferred partner for global clinical research programs.

Todd Rudo, the Chief Medical Officer at Clario, provides the scientific and medical leadership necessary to ensure the integrity of clinical trial data. Rudo architects the medical strategy that underpins the company endpoint technology platform, ensuring all solutions meet the rigorous requirements of regulatory bodies. The Chief Medical Officer oversees the scientific expertise team, guiding the application of clinical knowledge to decentralized, hybrid, and site-based trial models. Todd Rudo drives the development of evidence-based practices that enable pharmaceutical and biotechnology partners to achieve successful regulatory approvals. This leadership role involves collaborating with global teams across North America, Europe, and the Asia Pacific region to maintain the highest standards of clinical quality. By focusing on the intersection of medicine and technology, Rudo ensures that the organization delivers reliable clinical evidence that transforms lives, reinforcing the company position as a trusted leader in the clinical research technology sector.

Eric Schwartz, the Executive Vice President & Chief Legal Officer at Clario, directs the legal and compliance framework that governs the company global operations. Schwartz architects the strategies necessary to navigate the complex regulatory landscape of clinical trials, ensuring that all endpoint technology solutions adhere to international standards. The Executive Vice President & Chief Legal Officer oversees risk management, intellectual property protection, and corporate governance to support the company mission of delivering high-quality clinical evidence. Eric Schwartz drives the legal strategy for international expansion across North America, Europe, and the Asia Pacific region, ensuring compliance with regional medical and data privacy regulations. This role involves close collaboration with the executive team to mitigate legal risks while fostering innovation in clinical research technology. By maintaining a robust legal foundation, Schwartz ensures the organization operates with integrity and reliability, supporting the successful delivery of life-changing medical therapies to patients worldwide.